Pipeline
Overview
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Tedizolid phosphate (TR-701), formerly torezolid phosphate, an IV and orally administered second generation oxazolidinone, has successfully completed the first of two Phase 3 trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
In addition to Tedizolid phosphate (TR-701), Trius has two ongoing preclinical programs using our proprietary discovery platform to identify and develop antibiotics to treat infections caused by gram-negative and gram–positive bacteria.
Through funding under a contract with the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, our preclinical program targeting GyrB/ParE is focused on identifying and developing novel antibiotics to treat serious infections caused by gram-negative bacterial pathogens.
Our second preclinical program is a natural products program focused on identifying and developing novel antibiotics directed against broad spectrum (gram-positive and gram-negative) bacterial pathogens derived from marine microorganisms.
Under a government contract with the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, the marine natural products program is initially funded to identify and develop novel antibiotics for use as countermeasures for biodefense threats.